{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:14:32Z","timestamp":1789017272543,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116817","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:02:51Z","timestamp":1779688971000},"page":"116817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+\u202f\/HER2\u202f\u2212 metastatic breast cancer: A translational analysis of the GEICAM\/2013\u201302 PEARL trial"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-9120","authenticated-orcid":false,"given":"\u00c1ngel","family":"Guerrero-Zotano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-2718","authenticated-orcid":false,"given":"Miguel","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9995-5825","authenticated-orcid":false,"given":"Hanna","family":"Ritz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-4530","authenticated-orcid":false,"given":"Mireia","family":"Margel\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u00f6szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraf\u00edn Morales","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Reboredo","family":"Rendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4408-3999","authenticated-orcid":false,"given":"Pablo","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"de la Haba-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7385-1311","authenticated-orcid":false,"given":"Jes\u00fas","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Fisker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-962X","authenticated-orcid":false,"given":"Marta","family":"Portela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10286","key":"10.1016\/j.ejca.2026.116817_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116817_bib2","first-page":"5","article-title":"Optimizing therapeutic approaches for HR+\/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4\/6 inhibitor progression","volume":"8","author":"Cejalvo And\u00fajar","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejca.2026.116817_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103063","article-title":"Endocrine-based strategies after CDK4\/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis","volume":"142","author":"Escudero","year":"2026","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ejca.2026.116817_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116817_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.ejca.2026.116817_bib6","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1158\/1078-0432.CCR-23-0956","article-title":"Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive\/HER2-Negative Metastatic Breast Cancer Patients","volume":"29","author":"Pascual","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116817_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116817_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"52","key":"10.1016\/j.ejca.2026.116817_bib10","doi-asserted-by":"crossref","first-page":"17970","DOI":"10.1073\/pnas.0406332102","article-title":"Structures of thymidine kinase 1 of human and mycoplasmic origin","volume":"101","author":"Welin","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.ejca.2026.116817_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/1354750X.2023.2168063","article-title":"Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)","volume":"28","author":"Bergqvist","year":"2023","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib12","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1038\/s41598-020-61416-1","article-title":"Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","article-title":"Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib","volume":"19","author":"Bagegni","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.116817_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib15","first-page":"357","article-title":"Absolute assignment of breast cancer intrinsic molecular subtype","volume":"107","author":"Paquet","year":"2015","journal-title":"J Natl Cancer Inst enero De"},{"key":"10.1016\/j.ejca.2026.116817_bib16","series-title":"510(k) Substantial Equivalence Determination Decision Summary (Assay Only) [Internet]","author":"U.S. Food and Drug Administration","year":"2022"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10549-025-07879-0","article-title":"Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4\/6 and aromatase inhibitors","volume":"216","author":"Brown","year":"2026","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2026.116817_bib18","article-title":"Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4\/6 Inhibitors","volume":"10","author":"O\u2019Connor","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116817_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2021.12.030","article-title":"Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant","volume":"164","author":"Malorni","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12609-025-00585-2","article-title":"Promising Biomarkers in Breast Cancer: A Review of Thymidine Kinase","volume":"17","author":"Clifton","year":"2025","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.ejca.2026.116817_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.001","article-title":"Serum thymidine kinase activity in patients with HR-positive\/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial","volume":"186","author":"Malorni","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40644-016-0092-2","article-title":"Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: 18F-FAU, 18F-FMAU, and 18F-FLT","volume":"16","author":"McHugh","year":"2016","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol 24 De marzo De"},{"issue":"10","key":"10.1016\/j.ejca.2026.116817_bib24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1097\/JTO.0000000000000276","article-title":"Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report","volume":"9","author":"Nisman","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116817_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11307-016-1021-2","article-title":"Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases","volume":"19","author":"Heskamp","year":"2017","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116817_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-026-00904-5","article-title":"Dynamic biomarkers in hormone receptor-positive\/HER2-negative breast cancer trials: a new hope for precision oncology","volume":"12","author":"Di Grazia","year":"2026","journal-title":"NPJ Breast Cancer"},{"issue":"22","key":"10.1016\/j.ejca.2026.116817_bib27","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"10411","key":"10.1016\/j.ejca.2026.116817_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:53:40Z","timestamp":1781153620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0959804926005988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116817","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+\u202f\/HER2\u202f\u2212 metastatic breast cancer: A translational analysis of the GEICAM\/2013\u201302 PEARL trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116817"}}